Home › Funds › China Universal Asset Management Co., Ltd. › ALNY

China Universal Asset Management Co., Ltd. position in ALNY

ALNYLAM PHARMACEUTICALS INC · Health Care

China Universal Asset Management Co., Ltd. reported holding 25,269 shares of ALNY (ALNYLAM PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$7.6M, representing 0.45% of its reported portfolio and ranking #47 among its reported holdings. China Universal Asset Management Co., Ltd. has disclosed ALNY holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)25.27K sh
Reported value held$7.61M
Portfolio Weight0.45%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How China Universal Asset Management Co., Ltd.'s ALNY position evolved

China Universal Asset Management Co., Ltd. first disclosed a stake in ALNY in Q3 2023 at 3,580 shares (US$634K). The position peaked in Q3 2025 at 22,787 shares, worth US$10.4M. Across 12 filings, China Universal Asset Management Co., Ltd. increased the stake 6 time(s), trimmed it 5 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 25,269 shares valued at US$7.6M — a reduction of -1,997 shares quarter over quarter.. Notable position changes include a 631% increase in Q4 2023 (shares fell 22% over the following quarter), a 37% increase in Q1 2024 (shares rose 63% over the following quarter), a 37% increase in Q3 2024 (shares fell 14% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 3.58K $634.02K New
Q4 2023 26.16K $5.01M Add
Q1 2024 35.82K $5.35M Add
Q2 2024 26.51K $6.44M Reduce
Q3 2024 36.34K $9.99M Add
Q4 2024 39.00K $9.18M Add
Q1 2025 30.97K $8.36M Reduce
Q2 2025 27.82K $9.07M Reduce
Q3 2025 22.79K $10.39M Reduce
Q4 2025 25.27K $10.05M Add
Q1 2026 27.27K $9.02M Add
Q2 2026 25.27K $7.61M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ALNY and 13F data

ALNY (ALNYLAM PHARMACEUTICALS INC) is a Health Care company. 36 other funds we track also report a position in ALNY — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.70B), Baillie Gifford & Co (US$734.5M), Orbis Allan Gray Ltd (US$598.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ALNY

All ALNY fund holders →

FAQ

How long has China Universal Asset Management Co., Ltd. held ALNY?

China Universal Asset Management Co., Ltd. has disclosed ALNY holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is China Universal Asset Management Co., Ltd.'s current position in ALNY?

As of Q2 2026, China Universal Asset Management Co., Ltd. holds 25.27K shares of ALNY (ALNYLAM PHARMACEUTICALS INC), valued at $7.61M, representing 0.45% of its reported portfolio and ranking #47.

Has China Universal Asset Management Co., Ltd. been buying or selling ALNY?

In the latest 13F filing (Q2 2026), China Universal Asset Management Co., Ltd. reduced its position in ALNY. The position peaked in Q3 2025 at 22.79K shares.

Which other funds hold ALNY?

Other major institutional holders of ALNY include T. Rowe Price Investment Management, Inc., Baillie Gifford & Co, Orbis Allan Gray Ltd, among 36 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.